H.C. Wainwright upgraded Innate Pharma (IPHA) to Buy from Neutral with a $5 price target The company announced its intention to file an application with the FDA for an accelerated approval of lacutamab and initiate a Phase 3 study to evaluate the drug as a therapy for cutaneous T-cell lymphoma, the analyst tells investors in a research note. The firm recommends buying the stock’s recent weakness.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IPHA: